Table 1.
Baseline demographic and clinical characteristic of enrolled patients.
| Characteristics | Combination Group (N = 56) | TACE Group (N = 54) | P value |
|---|---|---|---|
| Gender | 1.000 | ||
| Female | 5 (8.9%) | 5 (9.3%) | |
| Male | 51 (91.1%) | 49 (90.7%) | |
| Age(years), median (range) | 51 (24 – 82) | 55 (29 – 80) | 0.041 |
| ≤55 | 37 (66.1%) | 28 (51.9%) | 0.129 |
| >55 | 19 (33.9%) | 26 (48.1%) | |
| Hypertension | 0.519 | ||
| Yes | 6 (10.7%) | 8 (14.8%) | |
| No | 50 (89.3%) | 46 (85.2%) | |
| Etiology | 0.718 | ||
| Hepatitis B | 43 (76.8%) | 43 (79.6%) | |
| Non-B Non-C | 13 (23.2%) | 11 (20.4%) | |
| ECOG PS | 0.535 | ||
| 0 | 49 (87.5%) | 45 (83.3%) | |
| 1 | 7 (12.5%) | 9 (16.7%) | |
| Child-Pugh score | 0.995 | ||
| 5 | 45 (80.3%) | 43 (79.6%) | |
| 6 | 8 (14.3%) | 8 (14.8%) | |
| 7 | 3 (5.4%) | 3 (5.6%) | |
| ALBI grade | 0.088 | ||
| 1 | 34 (60.7%) | 24 (44.4%) | |
| 2 | 22 (39.3%) | 30 (55.6%) | |
| BCLC stage | 0.738 | ||
| B | 17 (30.4%) | 18 (33.3%) | |
| C | 39 (69.6%) | 36 (66.7%) | |
| AFP(ng/mL), median(Q1, Q3) | 94.6 (4.1 – 1956.8) | 336.5 (25.2 – 2029.3) | 0.176 |
| ≤ 400 | 34 (60.7%) | 30 (55.6%) | 0.583 |
| >400 | 22 (39.3%) | 24 (44.4%) | |
| DCP(mAU/mL), median(Q1, Q3) | 377.5 (40.0 – 7984.0) | 818.0 (306.8 – 1312.3) | 0.246 |
| ≤ 664 | 32(57.1%) | 23 (42.6%) | 0.127 |
| > 664 | 24 (42.9%) | 31 (57.4%) | |
| Target tumor size (cm) | 0.703 | ||
| ≤ 7.5 | 27 (48.2%) | 28 (51.9%) | |
| > 7.5 | 29 (51.8%) | 26 (48.1%) | |
| Target tumor numbers | 0.367 | ||
| 1 | 13 (23.2%) | 12 (22.2%) | |
| 2 | 37 (66.1%) | 31 (57.4%) | |
| >=3 | 6 (10.7%) | 11 (20.4%) | |
| MVI | 0.890 | ||
| Absence | 37 (66.1%) | 35 (64.8%) | |
| Presence | 19 (33.9%) | 19 (35.2%) | |
| EHS | 0.565 | ||
| Absence | 27 (48.2%) | 29 (53.7%) | |
| Presence | 29 (51.8%) | 25 (46.3%) | |
| BMI (kg/m2), median (Q1, Q3) | 23.11 (20.78 – 25.06) | 22.90 (20.98 – 25.27) | 0.484 |
| PLT(x109/L), median (Q1, Q3) | 182 (142 – 221) | 156 (118 – 215) | 0.278 |
| NLR, median (Q1, Q3) | 3.22 (2.30 – 4.23) | 2.98 (2.01 – 3.86) | 0.374 |
| ALT(u/L), median (Q1, Q3) | 29 (18 – 46) | 33 (23 – 57) | 0.219 |
| ALP(u/L), median (Q1, Q3) | 125 (78 – 162) | 108 (86 – 161) | 0.645 |
| PT (sec), median (Q1, Q3) | 11.8 (11.3 – 12.6) | 12.0 (11.2 – 12.6) | 0.582 |
| TB(μmol/L), median (Q1, Q3) | 13.5 (10.7 – 18.6) | 14.5 (12.0 – 21.1) | 0.304 |
| ALB(g/L), median (Q1, Q3) | 40.6 (36.9 – 42.8) | 40.0 (36.6 – 42.0) | 0.312 |
| Cr(μmol/L), median (Q1, Q3) | 75.0 (66.3 – 85.8) | 72.5 (66.0 – 80.0) | 0.354 |
Data are presented as n (%) or median (Q1, Q3), Q1 and Q3 are 25th percent and 75th percent of interquartile range.
ECOG-PS, Eastern Cooperative Oncology Group performance status; ALBI grade albumin-bilirubin grade; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; DCP, Des-gamma carboxy prothrombin; MVI, macroscopic vascular invasion; EHS, extrahepatic spread; BMI, body mass index; PLT, platelet; NLR, neutrophil-to-lymphocyte ratio; ALP, alkaline phosphatase; PT, prothrombin time; TB, total bilirubin; ALB, albumin; Cr, creatinine.